Vitamin D Supplementation in Patients with Diabetes Mellitus Type 2 on Different Therapeutic Regimens: A One-Year Prospective Study on Cardiovascular Risk Factors

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 257-280-Disorders of Vitamin D Metabolism & Action
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-261
Khalid Alkharfy1, Nasser Mohmmed Al-Daghri*2, Shaun Sabico1, Abdulaziz Al-Othman1, Osama Moharram3, Majed SA Alokail4, Yousef Al-Saleh5, Sudhesh Kumar6 and George P. Chrousos7
1King Saud University, 2King Saud University, Riyadh, Saudi Arabia, 3King Abdulaziz University Hospital, 4King Saud Univ Coll of Sci, Riyadh, Saudi Arabia, 5King Saud University for Applied Health Sciences, 6Warwick Medical School, Coventry, West Midlands, United Kingdom, 7University of Athens School of Medicine, Athens, Greece
Purpose:  Little or no research has determined the effect of vitamin D3 supplementation in conjunction with non-pharmacological and pharmacological approaches in the type 2diabetes mellitus (DMT2) population. The purpose of this study was to determine the effect of vitamin D3 supplementation in a cohort of DMT2 patients on rosiglitazone, diet, insulin and/or different oral hypoglycemic agents (i.e., insulin + oral agents, metformin, and sulfonylureas) and compare them with a non-DMT2 control cohort.

Methods:  A total of 499 randomly selected subjects divided into 2 groups [non-DMT2 Controls=151; DMT2=348]. All DMT2 patients were given 2000 IU vitamin D3 daily, while the control group received none but were advised to increase sun exposure. Anthropometrics, glucose, lipid profile and 25-hydroxyvitamin D were measured at baseline, and at 6 and 12 months.

Results: Circulating 25-hydroxyvitamin D concentrations improved in all patient groups and the controls. The metformin group showed the highest change in circulating vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as compared to baseline (p < 0.001). Significant improvements were observed in systolic blood pressure, total- and HDL-cholesterol in male patients on insulin + oral agents after vitamin D supplementation (p-values<0.05). Significant decreases in triglycerides were also observed in the rosiglitazone and insulin + oral hypoglycemic agent groups both at 6 and 12 months of supplementation (p-values<0.001).

Conclusion: Vitamin D therapy at a dose of 2000 IU appears to alter cardiovascular disease risk factors under particular anti-diabetic regimens. Effects on well-being and other parameters need further study. 

Nothing to Disclose: KA, NMA, SS, AA, OM, MSA, YA, SK, GPC

*Please take note of The Endocrine Society's News Embargo Policy at

Sources of Research Support: This study has been graciously funded by the King Abdulaziz City of Science and Technology (KACST Grant no: AT-29-38), Riyadh, KSA.